DPZ, a selective mixed competitive and non-competitive reversible inhibitor of AChE, is an approved drug to treat mild to moderate symptoms associated with AD by the Food and Drug Administration (FDA) [38]. This evidence concerns the gene ACHE and Alzheimer disease.